Literature DB >> 29608934

Transition Points for the Routine Integration of Palliative Care in Patients With Advanced Cancer.

Anna Collins1, Vijaya Sundararajan2, Jodie Burchell2, Jeremy Millar3, Sue-Anne McLachlan4, Meinir Krishnasamy5, Brian H Le6, Linda Mileshkin7, Peter Hudson8, Jennifer Philip9.   

Abstract

CONTEXT: Increasing emphases are being placed on early integration of palliative care for patients with advanced cancers, yet barriers to implementation in clinical practice remain. Criteria to standardize referral have been endorsed, but their application is yet to be tested at the population level.
OBJECTIVES: This study sought to establish the need for standardized referral by examining current end-of-life care outcomes of decedents with cancer and define transition points within a cancer illness course, which are associated with poor prognosis, whereby palliative care should be routinely introduced to augment clinician-based decision making.
METHODS: Population cohort study of admitted patients with advanced cancer diagnosed with non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), prostate or breast cancer between 2000 and 2010 in Victoria, Australia, identified from routinely collected, linked, hospital discharge, emergency department, and death registration data. Descriptive statistics described quality indicators for end-of-life care outcomes for decedents. Kaplan-Meier analyses were used to test the predefined transition point that mostly accurately predicted survival of six months or lesser.
RESULTS: About 46,700 cases (56% females) were admitted with metastatic NSCLC (n = 14,759; 31.6%), SCLC (n = 2932; 6%), prostate (n = 9445; 20.2%), and breast cancer (n = 19,564; 41.9%). Of the 29,680 decedents, most (80%) died in hospital, had suboptimal end-of-life care outcomes (83%), and 59% received a palliative approach to care, a median of 27 days before death. Transition points in the cancer illness course of all cases were identified as first admission with any metastatic disease (NSCLC: 3.8 months [interquartile range {IQR} 1.1, 16.0]; n = 14,666; and SCLC: 4.2 months [IQR 1.0, 10.6]; n = 2914); first multiday admission with any metastatic disease (prostate: 6.0 months [IQR 1.3, 26.4]; n = 7174); and first multiday admission with at least one visceral metastatic site (breast: 6.0 months [IQR 1.2, 29.8]; n = 7120).
CONCLUSION: Despite calls for integrated palliative care, this occurs late or not at all for many patients with cancer. Our findings demonstrate the application of targeted cancer-specific transition points to trigger integration of palliative care as a standard part of quality oncological care and augment clinician-based referral in routine clinical practice.
Copyright © 2018 American Academy of Hospice and Palliative Medicine. All rights reserved.

Entities:  

Keywords:  Palliative care; cancer; health services research; integration

Mesh:

Year:  2018        PMID: 29608934     DOI: 10.1016/j.jpainsymman.2018.03.022

Source DB:  PubMed          Journal:  J Pain Symptom Manage        ISSN: 0885-3924            Impact factor:   3.612


  8 in total

1.  Randomized Trial of a Palliative Care Intervention to Improve End-of-Life Care Discussions in Patients With Metastatic Breast Cancer.

Authors:  Joseph A Greer; Beverly Moy; Areej El-Jawahri; Vicki A Jackson; Mihir Kamdar; Juliet Jacobsen; Charlotta Lindvall; Jennifer A Shin; Simone Rinaldi; Heather A Carlson; Angela Sousa; Emily R Gallagher; Zhigang Li; Samantha Moran; Magaret Ruddy; Maya V Anand; Julia E Carp; Jennifer S Temel
Journal:  J Natl Compr Canc Netw       Date:  2022-02       Impact factor: 11.908

2.  Palliative care to cancer patients: how COVID-19 pandemic could affect quality of care.

Authors:  Juliana Todaro; Camila Viale Nogueira; Elisa Rossi Conte; Rafael Aliosha Kaliks
Journal:  Einstein (Sao Paulo)       Date:  2022-05-27

3.  Experiences of End-of-Life Care of Older Adults with Cancer From the Perspective of Stakeholdersin Iran: A Content Analysis Study.

Authors:  Zohreh Ghezelsefli; Fazlollah Ahmadi; Eesa Mohammadi; Martine Puts Rn
Journal:  Asian Pac J Cancer Prev       Date:  2021-01-01

4.  A randomised phase II trial to examine feasibility of standardised, early palliative (STEP) care for patients with advanced cancer and their families [ACTRN12617000534381]: a research protocol.

Authors:  Jennifer Philip; Anna Collins; Brian Le; Vijaya Sundararajan; Caroline Brand; Susan Hanson; Jon Emery; Peter Hudson; Linda Mileshkin; Soula Ganiatsas
Journal:  Pilot Feasibility Stud       Date:  2019-03-14

5.  Examining public knowledge, attitudes and perceptions towards palliative care: a mixed method sequential study.

Authors:  Sonja McIlfatrick; Paul Slater; Esther Beck; Olufikayo Bamidele; Sharon McCloskey; Karen Carr; Deborah Muldrew; Lisa Hanna-Trainor; Felicity Hasson
Journal:  BMC Palliat Care       Date:  2021-03-17       Impact factor: 3.234

Review 6.  Quality indicators of palliative care for cardiovascular intensive care.

Authors:  Yoshimitsu Takaoka; Yasuhiro Hamatani; Tatsuhiro Shibata; Shogo Oishi; Akemi Utsunomiya; Fujimi Kawai; Nobuyuki Komiyama; Atsushi Mizuno
Journal:  J Intensive Care       Date:  2022-03-14

7.  The feasibility of triggers for the integration of Standardised, Early Palliative (STEP) Care in advanced cancer: A phase II trial.

Authors:  Anna Collins; Vijaya Sundararajan; Brian Le; Linda Mileshkin; Susan Hanson; Jon Emery; Jennifer Philip
Journal:  Front Oncol       Date:  2022-09-15       Impact factor: 5.738

8.  Care plus study: a multi-site implementation of early palliative care in routine practice to improve health outcomes and reduce hospital admissions for people with advanced cancer: a study protocol.

Authors:  Jennifer Philip; Roslyn Le Gautier; Anna Collins; Anna K Nowak; Brian Le; Gregory B Crawford; Nicole Rankin; Meinir Krishnasamy; Geoff Mitchell; Sue-Anne McLachlan; Maarten IJzerman; Robyn Hudson; Danny Rischin; Tanara Vieira Sousa; Vijaya Sundararajan
Journal:  BMC Health Serv Res       Date:  2021-05-27       Impact factor: 2.655

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.